anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ovulation induction: regular Clomiphene Citrate protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. At the same time, take CC 100mg/d until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
Lymph node metastasis (LNM) occurs in less than 5% of soft tissue sarcoma (STS) patients and indicates an aggressive course of disease. Suspicious lymph nodes (LN) in staging imaging are a frequent topic of discussion in multidisciplinary tumor boards. Predictive markers are needed to facilitate stratification and improve treatment of STS patients. In this study, 56 STS patients with radiologically suspicious and subsequently histologically examined LN were reviewed. Patients with benign (n = 26) and metastatic (n = 30) LN were analyzed with regard to clinical, laboratory and imaging parameters. Patients with LNM exhibited significantly larger short axis diameter (SAD) and long axis diameter (LAD) vs. patients with benign LN (median 22.5 vs. 14 mm, p < 0.001 and median 29.5 vs. 21 mm, p = 0.003, respectively). Furthermore, the presence of central necrosis and high maximal standardized uptake value (SUVmax) in FDG-PET-CT scans were significantly associated with LNM (60 vs. 11.5% of patients, p < 0.001 and median 8.59 vs. 3.96, p = 0.013, respectively). With systemic therapy, a slight median size regression over time was observed in both metastatic and benign LN. Serum LDH and CRP levels were significantly higher in patients with LNM (median 247 vs. 187.5U/L, p = 0.005 and 1.5 vs. 0.55 mg/dL, p = 0.039, respectively). This study shows significant associations between LNM and imaging features as well as laboratory parameters of STS patients. The largest SAD, SUVmax in FDG-PET-CT scan, the presence of central necrosis, and high serum LDH level are the most important parameters to distinguish benign from metastatic LNs.
Patients who underwent thoracotomy operation in our hospital between May 2016 and June 2017 were examined. A retrospective evaluation was made of the data that was retrieved from the records of a total of 49 patients aged 18-75 years, ASA I-III, who were applied with Intercostal (IB) or Serratus anterior plane(SAPB) for a thoracotomy operation. The patient information was retrieved from the patient records and anesthesia block forms. The data were examined in respect of age, sex, height, weight, ASA, operation type, operating time, the amount of postoperative analgesic consumption, VAS at 1.,2.,4.,6.,12.,24. hours and complications (atelectasis, nausea, vomiting, hypotension and bradycardia).

Statistical analysis was performed using the SPSS program for Mac, version 17.0 (SPSS,Chicago,IL). Descriptive statistics are presented as mean and SD, and as the number of cases (n) and the corresponding percentage (%) for nominal variables. T tests were performed for normally continuous variables. The Mann-Whitney U test was used for non-parametric variables. A value of p \< 0.05 was considered statistically significant.
The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 1 (mid dose) will be applied.
The present invention relates to drug world, be specifically related to the polypeptide compound preventing and treating or prevention of arterial is atherosis. Thrombin suppresses polypeptide 2, it is characterised in that: its sequence is RGDLFRKSADGFIALMKLKK. Prepared by the solid phase synthesis technique adopting Fmoc protection. Can a covalently bound adjuvant, adjuvant is bovine serum albumin, human serum albumin, or Polyethylene Glycol. Thrombin suppresses the polypeptide 2 application in treatment atherosclerosis relevant disease. Described atherosclerosis relevant disease is the pathological changes such as angina pectoris, myocardial infarction, arrhythmia, apoplexy, brain atrophy, intractable hypertension, renal insufficiency. Can treating atherosclerosis relevant disease by multiple administering mode, including subcutaneously or intramuscularly injecting, intravenous injection or intravenous drip, oral administration is pill, capsule etc. such as, nasal spray etc. Thrombin in the present invention suppresses the polypeptide 2 can targeted inhibition thrombin, it is suppressed that blood coagulation, reaches prevention or treats atherosclerotic effect.
Geriatric depression, also known as late-life depression, is a type of major depression that affects people who are 60 years old or older. It can be difficult to treat and often comes back after treatment. It can also lead to problems with memory and thinking. Some studies have found that problems with the white matter in the brain can make it harder to treat depression in older adults. White matter helps with communication in the brain. A new study suggests that a medicine called clemastine might be able to improve the white matter in the brain. Clemastine is usually used as an antihistamine, but it might also help the brain repair itself. The goal of this study is to find out if clemastine can make the white matter in the brain better in older adults with depression. The study will also determine whether this improvement can make antidepressant treatment work better, reduce depressive symptoms, and improve memory and thinking. The study will involve two groups of participants. One group will receive the standard antidepressant treatment along with a placebo, while the other group will receive the standard antidepressant treatment along with clemastine. The investigators will compare the effects of these two treatments over a period of 12 weeks. The investigators will measure the improvement in white matter using special brain imaging techniques. The investigators will also assess the participants' mood, memory, and thinking abilities, and keep track of any side effects or problems caused by the treatments. Overall, this study has the potential to contribute valuable insights into the treatment of geriatric depression, alleviate depressive symptoms, enhance cognitive function, and potentially open up new avenues for future research and therapeutic approaches.
The PIRA study aims to evaluate the metabolic and inflammatory effects after a vegan meal or a meal containing red meat or fish in patients with RA and matched controls. The study have a cross-over design and each participant will have one of three meals every week and then be compared to themselves. In addition healthy individuals will be included for the red meat meal so that the response from this meal could be compared between patients with RA and their matched controls. Blood samples will be collected before the meal (fasting) and every hour until 5h. Primary outcome will be high sensitive IL-6. Secondary outcomes will be additional inflammation markers such as area under curve for hs-CRP and gene expression in PBMC:s regarding genes related to inflammation and, glucose, blood lipids and metabolomics-profile in serum and urine.
About 200 million people worldwide live at high altitudes and millions of others travel to high altitude every year for work or pleasure. At high altitude participants are exposed to a lower than normal level of oxygen, also known as hypoxia. This causes stress to the human body, which will adapt in order to maintain adequate oxygen delivery to its tissues. One of these adaptations is an increase in activity of participants' sympathetic nervous system ("fight or flight" response). Sympathetic nerve activity affects the size of participants' blood vessels, which in turn will affect blood pressure. Men and women regulate their blood pressure in different ways; for example, women tend to have lower blood pressure and sympathetic nerve activity than men. Women also appear to have less constriction of their blood vessels in response to stress. This may be in part because estrogen causes blood vessels to dilate. It may also be due to differences in the receptors which are activated by the sympathetic nervous system. These receptors are called alpha and beta receptors and respond to sympathetic nerve activity in opposite directions. Women represent 50% of the population living at and travelling to high altitude, therefore, it is important to understand the differences in how men and women respond to low oxygen.

The main purpose of this study is to examine the differences between men and women in the sympathetic nervous system control of blood vessels during exposure to low oxygen. To study this question, the investigators will test how blood vessels respond to stressors in both men and women. Participants will be recruited at the Canadian sites, and the investigators will test them while they breathe low oxygen for a short amount of time at low altitude. The investigators will also perform assessments on the same participants during a two week stay at high altitude at White Mountain, CA, which is at an altitude of 3,800m. These data will have implications in the basic understanding of differences between male and female physiology. Specifically, to males and females living or travelling to high altitude.
The estimated prevalence of overweight and obese individuals \>20 years in the US is 154.7 million (nearly double since the early 1960s), and over 1.6 billion people are considered overweight or obese worldwide. Compounding the health risks associated with obesity is the insufficient data supporting dosing strategies for a variety of medication used to treat conditions encountered in obese patients. No consensus on the best dosing strategy for IgG in obese patients has been established. Total (TBW), ideal (IBW), and adjusted (AdjBW) body weight-based dosing are being utilized by different institutions. Thus, there is an urgent need to identify evidence supporting optimal dosing strategies for IgG.

It has been proposed that using TBW to dose IgG in obese patients may increase the risk of thrombosis owing to increased blood viscosity, activation of platelets, or vasospasm; and the increase in blood viscosity has been reported as IgG dose dependent. The use of using IBW or AdjBW has been advocated to reduce the side effect and drug expenditures. It is currently unknown what the clinical impact is of using measures of body weight other than TBW to calculate IgG doses, and the effect of obesity on IgG pharmacokinetics has not been experimentally evaluated.
The invention discloses a preparation method and application of a loquat leaf triterpenic acid component nano-emulsion, which comprises the following steps: weighing 50mg of loquat leaf triterpenic acid component and 500mg of poloxamer 188, dissolving in 12.5mL of isopropyl myristate, slowly dripping the solution into 37.5mL of high-purity water, and uniformly and continuously stirring for 2h to obtain the O/W type nanoemulsion. The particle size is 76.8 +/-1.6 nm, and the polydispersity index (PDI) is 0.22 +/-0.03, which indicates that the particle size meets the requirement of passive targeting of the nanoemulsion; zeta is-30.2 +/-1.8, granuleThe intermolecular repulsive force is larger, which shows that the nanoemulsion has better stability; the encapsulation efficiency is 88.32 +/-3.42%, the drug loading rate is 8.68 +/-0.35%, and the nano-emulsion has excellent drug loading performance. MTT experiment finds. After the nano-emulsion is prepared, the triterpenic acid component of the loquat leaves has an enhanced effect of inhibiting Lewis of lung cancer cells, and the Lewis lung cancer cells are incubated for 24h of IC 50 From 32.27. mu. mol. L ‑1 Reduced to 24.89 mu mol & L ‑1 (ii) a The lung cancer cells are incubated with the loquat leaf triterpenic acid component nanoemulsion for 2h, and the uptake rate is increased from 25.71% to 46.05%.
BACKGROUND: Patients with prior coronary artery bypass grafting (CABG) presenting with an acute coronary syndrome (ACS) have poor outcomes and the optimal treatment strategy for this population is unknown.
METHODS: Using linked administrative databases, we examined patients with an ACS between 2008 and 2019, identifying patients with prior CABG. Patients were categorized by ACS presentation type and treatment strategy. Our primary outcome was the composite of death and recurrent myocardial infarction at one year.
RESULTS: Of 54,641 patients who presented with an ACS, 1670 (3.1%) had a history of prior CABG. Of those, 11.0% presented with an ST-elevation myocardial infarction (STEMI) of which, 15.3% were treated medically, 31.1% underwent angiography but were treated medically, 22.4% with fibrinolytic therapy and 31.1% with primary PCI. The primary outcome rate was the highest (36.8%) in patients who did not undergo angiography and was similar in the primary PCI (20.8%) and fibrinolytic group (21.9%). In patients presenting with a non-ST elevation acute coronary syndrome (NSTE-ACS) (89.0%), 33.2% were treated medically, 38.5% underwent angiography but were treated medically and 28.2% were treated with PCI. Compared to those who underwent PCI, patients treated conservatively demonstrated a higher risk of the composite outcome (14.8% vs 27.3%; adjusted hazard ratio 1.70, 95% confidence interval 1.22-2.37).
CONCLUSIONS: Patients with prior CABG presenting with an ACS are often treated conservatively without PCI, which is associated with a higher risk of adverse events.
PURPOSE: A wearable device assembly with an exercise function is provided to easily perform recording and monitoring using a universal serial bus (USB) device. CONSTITUTION: A device assembly (10) comprises a control unit and a housing. The control unit comprises one or more sensors (2). The control unit detects the activity of a user. The control unit shows an activity level of the user. The control unit selectively radiates a display unit system.
Studies in humans and mice have determined that distinct subpopulations of adipocytes reside even within individual adipose tissue depots. Previously, our lab defined three white adipocyte subpopulations with stable and unique gene expression profiles, which were termed type 1, 2, and 3 adipocytes, respectively. Our previous studies demonstrated that type 2 adipocytes were highly responsive to the inflammatory cytokine, tumor necrosis factor alpha (TNFα). This study extends these findings to investigate the role of type 2 adipocytes in obesity. We found that treatment with TNFα increased lipolysis specifically in type 2 adipocytes, at least in part, through the reduction of fat-specific protein 27 (FSP27) expression. To assess the physiological role of lipolysis from this adipocyte subpopulation, a type2Ad-hFSP27tg mouse model was generated by overexpressing human FSP27 specifically in type 2 adipocytes. Glucose and insulin tolerance test analysis showed that male type2Ad-hFSP27tg mice on 60% high-fat diet exhibited improved glucose tolerance and insulin sensitivity, with no change in body weight compared to controls. These metabolic changes may, at least in part, be explained by the reduced lipolysis rate in the visceral fat of type2Ad-hFSP27tg mice. Although FSP27 overexpression in primary type 2 adipocytes was sufficient to acutely reduce TNFα-induced apoptosis in vitro, it failed to reduce macrophage infiltration in obesity in vivo. Taken together, these results strongly suggest that type 2 adipocytes contribute to the regulation of lipolysis and could serve as a potential therapeutic target for obesity-associated insulin resistance.
Patients receive nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress after 10 weeks on single agent nivolumab may elect to cross over to Arm II.
The control algorithm will automatically direct between meals and meal-related subcutaneous insulin delivery utilizing real-time continuous glucose monitoring (RT-CGM) data. The subcutaneous insulin pump will deliver insulin Aspart or similar. In phase 1, a once daily basal insulin analogue will also be given subcutaneously at 20% the patient's usual total daily dose. In phase 3 and 4 faster-acting insulin aspart (Fiasp) is applied.
PURPOSE:To provide a long-acting tablet capable of releasing the drug component continuously at a constant rate by the control of the disintegrability and keeping the drug action for a long period, producible easily, and composed of wax and disintegrable granule containing a principal drug or a principal drug and a water-soluble polymer. CONSTITUTION:A disintegrable granule containing a principal drug or principal drug and a water-soluble polymer (e.g. cellulose derivative, polysaccharide, etc.) and a disintegrant (e.g. starch, gum, cellulose derivative, etc.) is coated with a wax and tableted to obtain a long-acting tablet. The amount of the disintegrant is preferably 10-60wt% based on the components of the granule, and that of the water-soluble polymer is preferably 2.5-45wt%. The amount of wax is preferably 30-55wt% of the tablet. The tablet has nearly constant rate of drug release, and the variations of the stirring rate and pH have little effect on the rate of drug release.
Systems and techniques relating to evaluating performance characteristics are provided. One or more fitness devices, for example, a ball and/or a mat, may have sensors for measuring a user's actions during an activity protocol, such as a testing drill. Sensor configured to detect if the fitness device meets operational criteria are disclosed. In one embodiment, the fitness device may comprise a ball and the operational criteria may relate to the weight, dimensions, and/or internal pressure of the ball. In one embodiment, data from fitness device(s) may be used to calculate a score. In other embodiments, a score may be calculated; however, it may not be associated with credentials or certified if an operational criteria is not met.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to an amide derivative of the general formula (I')   where symbols in formula have the following values: D means pyrazolyl group that can comprise 1-3 halogen-substituted or unsubstituted lower alkyl groups as substituent(s); B means phenylene or thiophenediyl group; X means group of the formula +NH-CO- or +CO-NH-; A means phenyl group that can be substituted with one or some halogen atoms or five- or six-membered monocyclic heteroaryl group that can be substituted with one or more lower alkyl groups. Invention describes also a pharmaceutical composition based on the claimed compounds that is designated for inhibition of isolation of Ca 2- -channels activated by secreted Ca 2+ . Compounds can be used as an agent used for prophylaxis or treatment of different inflammatory and allergic diseases. EFFECT: valuable medicinal properties of compound. 9 cl, 1 tbl
<P>PROBLEM TO BE SOLVED: To provide a medical image processor, a medical network system and a program for the medical image processor which prevent the information of the images other than that of those desired to be altered during the same examination from being altered without users' awareness, the information of the images other than that of those desired to be altered during the same examination from being altered without notice that the images themselves are already outputted and the images other than those of the patients intended during the diagnosis from being diagnosed.  <P>SOLUTION: In the medical image processor, the medical image information is received from other devices, undergoes an image processing and the results are transmitted to other devices to alter the information attached to the images. The information attached to the images to be altered is judged whether to be the information on an image basis or to be that on an examination basis and it is selected whether the information is altered on an examination basis or on an image basis. When the information to be altered is the one on an examination basis, the selection screen is displayed. But when the altering of the information on an image basis is selected, the images on an examination basis are preserved as those for other examinations being separated from the current examination.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Subjects received treatment up to 1764 days during the Evaluation Period. Up to 4000 mg/day (or 80 mg/kg/day for children and adolescents less than 50 kg). Oral tablets of 166, 250, or 500 mg Levetiracetam twice daily (b.i.d.).
Participants will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer. Once a week, the exercise trainer and participant will each log on to Zoom from their locations to begin the supervised exercise session. The exercise trainer will record all sessions. Sessions will be 30 to 45 minutes long and be structured as follows: review of previous session and an opportunity to ask questions; 5-minute warm-up; 20- to 25-minute workout; 5- to10-minute cool down and reminder of next session and/or data collection time period. Supervised sessions will be scheduled once a week over the 12-week intervention. Participants will be expected to complete their resistance-based physical activity program for an additional 1-2 days a week as per the intervention schedule to meet as physical activity guidelines. The exercise trainer will track participant attendance. During the session, participants must have another person in the same location in case of an emergency.
The present invention relates to a cosmetic composition containing an extract of Morinda officinalis Haw. as an active ingredient. The present invention is characterized by containing 0.0001 to 30.0% by weight of the extract of Morinda officinalis Haw. as an active ingredient based on the total weight of the cosmetic composition. According to the present invention, the extract of Morinda officinalis Haw. has a skin anti-aging effect and specifically has an MMP-1 production inhibiting effect, a collagen biosynthesis effect, a preservative effect, an anti-oxidative effect, a skin wrinkle improvement effect, a skin elasticity improvement effect, and a moisture effect to supply the functional cosmetic.
Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.
d-a -Tocopherol is distinguished from dl-a -tocopherol, which has a different biological activity, by reacting the a -tocopherol with a ferricyanide in aqueous alkaline solution, which is effective to convert d-a -tocopherol to a product having positive specific optical rotation and ineffective to convert dl-a -tocopherol to a product having specific optical rotation, and ascertaining the optical activity of the product. A d-a -tocopheryl ester may be distinguished from a dl-a -tocopheryl ester by first hydrolysing the ester to the corresponding a -tocopherol and then reacting it with the ferricyanide. Examples are given.ALSO:d-a -tocopherol is distinguished from dl-a -tocopherol, which has a different biological activity, by reacting the a -tocopherol with a ferricyanide in aqueous alkaline solution, which is effective to convert d-a -tocopherol to a product having positive specific optical rotation and ineffective to convert dl-a -tocopherol to a product having specific optical rotation, and ascertaining the optical activity of the product.  A d-a -tocopheryl ester may be distinguished from a dl-a -tocopheryl ester by first hydrolysing the ester to the corresponding a -tocopherol and then reacting it with the ferricyanide. Examples are given.  The test distinguishes between natural (d) and synthetic (dl) a -tocopherols.